Un audited Financial results for the quarter and half-year ended 30.09.2025
Awaiting price reaction for this filing.
Sangam Health Care Products reported Q2 FY26 (quarter ended 30 Sept 2025) net sales of Rs. 304.01 lakhs, down about 16% from Rs. 361.96 lakhs in the same quarter last year. For the half-year (H1 FY26), revenue declined to Rs. 585.67 lakhs versus Rs. 701.14 lakhs in H1 FY25, a drop of around 16.5%. Despite weaker sales, profit after tax jumped sharply — Q2 PAT rose to Rs. 23.36 lakhs (vs Rs. 7.24 lakhs a year ago) and H1 PAT more than doubled to Rs. 33.62 lakhs (vs Rs. 15.34 lakhs), driven by lower raw material and employee costs. The board cleared these results along with a limited review report from statutory auditors M M Reddy & Co, which is clean with no qualifications.
Top-line continues to shrink year-on-year, which is a worry, though margins have improved sharply on cost cuts. Shareholders should note that the balance sheet shows negative net worth of about Rs. (2,006) lakhs (accumulated losses exceeding share capital), high long-term borrowings of Rs. 2,403 lakhs, and negative operating cash flow of Rs. (236) lakhs — these are significant financial health red flags despite the short-term PAT improvement.